The finding addresses a central problem in cancer immunology. Anti-PD-1 therapy does not work simply because a drug is present in the bloodstream; it depends on a coordinated interaction between tumor cells, immune cells, connective-tissue-producing cells and inflammatory signals. In some hepatocellular carcinomas, the tumor is embedded in a dense, scar-like network created by fibroblasts and other stromal cells. This fibroinflammatory microenvironment can restrict the movement of immune cells, alter the chemical signals reaching the tumor and help malignant cells avoid immune destruction. In effect, the tumor becomes biologically concealed even when the immune system has been pharmacologically released from PD-1 inhibition.

The study focuses on peroxisome proliferator-activated receptor alpha, or PPARα, a nuclear receptor that controls broad aspects of lipid metabolism, energy use and inflammatory signaling. Nuclear receptors function as transcriptional regulators: after activation, they can enter the nucleus or influence nuclear gene programs, changing the expression of multiple proteins at once. Because liver cells are highly dependent on metabolic regulation, PPARα has particular significance in hepatic biology. Chen and colleagues investigated whether activating this pathway could change the conditions that allow fibroinflammatory liver tumors to resist anti-PD-1 treatment.

Their proposed mechanism involves gasdermin E, commonly known as GSDME. Gasdermins are proteins capable of forming pores in the cell membrane when released from an inactive precursor. GSDME-dependent pyroptosis is a highly inflammatory form of programmed cell death. Unlike the relatively quiet dismantling associated with apoptosis, pyroptosis causes the affected cell to swell and rupture, releasing intracellular molecules that can alert and recruit immune cells. This process can convert the death of a tumor cell into an immunological signal, potentially helping the immune system recognize and attack neighboring malignant cells.

According to the study, PPARα activation increased the susceptibility of hepatocellular carcinoma cells to this GSDME-mediated process, helping anti-PD-1 therapy produce a stronger antitumor effect. The significance of the result lies not only in the destruction of individual cancer cells, but also in the possibility that pyroptosis may reshape the communication between tumor cells and the surrounding immune microenvironment. When tumor cells undergo inflammatory death, they can release danger-associated molecular patterns and other signals that stimulate immune surveillance. In principle, this can create a reinforcing cycle in which immune activation leads to more tumor-cell killing, which then generates additional immune stimulation.

The fibroinflammatory environment remains an important part of the story. Tumor-associated fibroblasts and the extracellular matrix they produce are not passive scaffolding; they can influence cancer growth, drug penetration and immune-cell behavior. Excessive fibrosis may physically complicate access to malignant cells, while inflammatory mediators can produce an immunosuppressive landscape. By linking PPARα activity to GSDME-dependent pyroptosis, the researchers suggest that a metabolic intervention may help weaken this barrier without relying exclusively on direct stromal destruction. The approach could therefore represent a form of microenvironmental reprogramming, in which the tumor is made more visible and vulnerable to immune attack.

The work also highlights why combinations are increasingly important in modern oncology. PD-1 blockade targets an immune checkpoint, but checkpoint inhibition alone cannot guarantee that a tumor contains sufficient danger signals or that immune cells can effectively engage cancer cells. A PPARα-directed treatment could provide a complementary function by changing tumor-cell metabolism and death behavior. Rather than replacing immunotherapy, it may make the existing treatment biologically more effective. Such a strategy is especially relevant for patients whose tumors show features of fibroinflammatory resistance, although identifying those patients will require reliable molecular and tissue-based biomarkers.

The findings should be interpreted as a mechanistic advance rather than immediate proof of a new standard treatment. PPARα has complex roles in normal liver metabolism and in cancer biology, and its effects may depend on tumor subtype, treatment dose and the condition of the surrounding tissue. Likewise, pyroptosis can be beneficial when it stimulates productive antitumor immunity, but excessive or poorly controlled inflammation could damage healthy tissue or create other complications. Future studies will need to determine how consistently the pathway operates in human tumors, whether PPARα activation can be safely combined with approved checkpoint inhibitors and which molecular signals best predict benefit.

For hepatocellular carcinoma, the report offers a compelling example of how cancer resistance can be attacked from several directions at once. The tumor is not merely a mass of malignant cells; it is an ecosystem shaped by metabolism, fibrosis, inflammation and immune surveillance. By connecting PPARα activation with GSDME-dependent pyroptosis, Chen and colleagues propose a way to turn a resistant liver tumor from an immunologically sheltered site into a source of inflammatory signals. If validated in further preclinical research and clinical trials, the strategy could expand the reach of anti-PD-1 therapy and provide a new framework for treating cancers protected by fibroinflammatory microenvironments.

Subject of Research: PPARα activation, GSDME-dependent pyroptosis, fibroinflammatory liver tumor microenvironment and anti-PD-1 resistance in hepatocellular carcinoma

Article Title: PPARα activation overcomes fibroinflammatory liver microenvironment-associated anti-PD-1 resistance in hepatocellular carcinoma by mediating GSDME-dependent pyroptosis

Article References: Chen, P., Xiong, K., Huang, K. et al. PPARα activation overcomes fibroinflammatory liver microenvironment-associated anti-PD-1 resistance in hepatocellular carcinoma by mediating GSDME-dependent pyroptosis. Nat Commun (2026). https://doi.org/10.1038/s41467-026-75770-7

Image Credits: AI Generated

DOI: 10.1038/s41467-026-75770-7

Keywords: hepatocellular carcinoma, PPARα, GSDME, pyroptosis, anti-PD-1 therapy, immunotherapy resistance, fibroinflammatory microenvironment, tumor metabolism

NSCLC remains one of the leading causes of cancer-related mortality worldwide, frequently presenting challenges due to resistance to apoptosis, the most commonly targeted cell death pathway in cancer therapies. The discovery that fosinopril induces pyroptosis, rather than apoptosis, marks a significant paradigm shift. Pyroptosis is a form of lytic programmed cell death characterized by cellular swelling, membrane rupture, and inflammatory cytokine release. This form of cell death, mediated through gasdermin family proteins, offers a promising alternative to eradicate cancer cells that evade apoptosis.

Central to this mechanism is gasdermin E (GSDME), a protein that, when cleaved, forms pores in the plasma membrane, leading to cell swelling and lysis. The study meticulously delineates how fosinopril activates caspase proteins, which in turn cleave GSDME, unleashing its pyroptotic function. This process contrasts significantly with the classical apoptosis pathway, where cells undergo controlled dismantling without eliciting inflammation, underscoring an innovative anti-cancer modality that not only kills the tumor cells but potentially activates an immune response against the tumor microenvironment.

The researchers utilized both in vitro and in vivo NSCLC models to validate fosinopril’s efficacy. At the molecular level, they observed increased expression and cleavage of GSDME following fosinopril treatment, correlating with enhanced pyroptotic markers such as cell swelling and lactate dehydrogenase (LDH) release. These pyroptotic events culminated in a marked reduction of tumor cell viability and tumor burden in animal models, suggesting a potent antitumor effect mechanistically linked to pyroptosis induction.

Further molecular analyses revealed that fosinopril’s induction of pyroptosis is intricately tied to the activation of upstream caspases, particularly caspase-3, known to bridge apoptotic and pyroptotic pathways by cleaving GSDME. This cleavage releases the GSDME N-terminal domain, which oligomerizes within the plasma membrane, generating pores that rupture the cell membrane, expelling intracellular contents and alerting the immune system. The inflammatory milieu engendered by pyroptosis could synergistically enhance anti-cancer immunity, a feature absent in apoptosis-driven therapies.

This study pioneers the repositioning of fosinopril beyond its conventional role as an angiotensin-converting enzyme (ACE) inhibitor. The molecular crosstalk between the renin-angiotensin system and pyroptotic pathways had remained largely unexplored prior to this investigation. By delineating these unexpected interactions, the authors provide a compelling rationale for clinical trials aiming to harness fosinopril’s dual functions, potentially improving NSCLC outcomes while capitalizing on its known safety profile.

The implications of this research extend deep into the clinical realm, where resistance mechanisms often limit the efficacy of targeted therapies and immunotherapies in NSCLC. Leveraging pyroptosis as a therapeutic endpoint offers a novel mode of action that might circumvent existing resistance and potentiate combination therapies. Moreover, the inflammatory aftermath of pyroptosis could enhance tumor antigen presentation and immunogenicity, possibly converting “cold” tumors resistant to immunotherapy into “hot,” more responsive ones.

Crucially, the researchers also addressed possible off-target effects and toxicity, conducting comprehensive assessments across various non-cancerous cell lines. Their data underscored a favorable therapeutic window where fosinopril selectively triggered pyroptosis in tumorigenic cells with minimal cytotoxicity in normal pulmonary tissues. This selectivity hints at mechanistic nuances within cancer cells’ microenvironment or genetic landscape that sensitize them to GSDME-mediated pyroptosis.

Mechanistically, the study delves into the signaling pathways upstream of caspase activation, uncovering involvement of mitochondrial dysfunction and reactive oxygen species (ROS) generation. Fosinopril treatment resulted in mitochondrial membrane potential disruption, elevating intracellular ROS, which serves as a pro-apoptotic and pyroptotic stimulus. These findings highlight a multifactorial process where fosinopril orchestrates a complex interplay of signals culminating in cancer cell death.

While previous studies have implicated pyroptosis in infectious and inflammatory diseases, its therapeutic exploitation in oncology remains nascent. This research serves as a landmark, suggesting that repurposing classical drugs to exploit this pathway can accelerate translational efforts. The authors propose that targeting GSDME expression or function could be customized to individual patient tumors, tailoring treatments based on the tumor’s molecular profile and pyroptotic susceptibility.

The study also explored synergistic potential by combining fosinopril with existing chemotherapeutic agents. Preliminary data indicated enhanced efficacy, possibly through additive or cooperative induction of cell death pathways. This combinatorial approach could mitigate limitations of monotherapy and offer robust therapeutic responses in diverse NSCLC patient populations.

On a broader scale, the ability to induce pyroptosis selectively in tumor cells may herald transformative shifts in cancer immunotherapy. The immunogenic nature of pyroptotic cell demise, characterized by the release of pro-inflammatory cytokines such as IL-1β and IL-18, offers a template for in situ tumor vaccination strategies. Fosinopril may thus serve as a prototype for designing drugs that couple cytotoxicity with immune activation, an intersection critical for durable cancer control.

The researchers also emphasize the need for extensive clinical validation, recognizing that translating these promising preclinical outcomes into effective human therapies will necessitate rigorous pharmacokinetic and pharmacodynamic studies. Variables such as dosage optimization, delivery modalities, and patient stratification based on GSDME expression levels will be pivotal for maximizing therapeutic benefits while minimizing adverse effects.

Moreover, the broader implications for ACE inhibitors in oncology warrant reevaluation, as fosinopril’s anticancer properties could inspire systematic screening of related compounds for pyroptotic activity. This could foster a new class of anti-cancer agents that repurpose existing drugs, thereby shortening development timelines and enhancing patient accessibility.

In conclusion, the study by Gao, Zhai, Zhang, and colleagues represents a quantum leap in lung cancer therapeutics, revealing a previously unrecognized mechanism by which fosinopril exerts antitumor effects via GSDME-dependent pyroptosis. This work not only broadens the mechanistic understanding of cancer cell death but also paves the way for innovative, immune-activating treatment strategies against NSCLC, a cancer subtype in urgent need of novel therapeutic options.

Subject of Research: The investigation focuses on fosinopril’s antitumor effects mediated through the induction of gasdermin E (GSDME)-dependent pyroptosis in non-small cell lung cancer (NSCLC).

Article Title: Fosinopril mediates antitumor efficacy by inducing GSDME-dependent pyroptosis in NSCLC.

Article References:
Gao, Y., Zhai, X., Zhang, C. et al. Fosinopril mediates antitumor efficacy by inducing GSDME-dependent pyroptosis in NSCLC. Cell Death Discov. 11, 540 (2025). https://doi.org/10.1038/s41420-025-02791-4

Image Credits: AI Generated

DOI: 21 November 2025